{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T12:49:08Z","timestamp":1717937348539},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T00:00:00Z","timestamp":1275955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00280-010-1370-5","type":"journal-article","created":{"date-parts":[[2010,6,7]],"date-time":"2010-06-07T08:50:27Z","timestamp":1275900627000},"page":"993-998","source":"Crossref","is-referenced-by-count":10,"title":["Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients"],"prefix":"10.1007","volume":"66","author":[{"given":"Franca","family":"Formelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cavadini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Luksch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Garaventa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Appierto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Persiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,8]]},"reference":[{"key":"1370_CR1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ijc.20923","volume":"115","author":"F Chiesa","year":"2005","unstructured":"Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, Cavadini E, Formelli F, Costa L, Giardini R, Zurrida S, Costa A, De Palo G, Veronesi U (2005) Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 115:625\u2013629","journal-title":"Int J Cancer"},{"key":"1370_CR2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/annonc\/mdl047","volume":"17","author":"U Veronesi","year":"2006","unstructured":"Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB, De Palo G (2006) Fifteen-year results of a randomized phase III of fenretinide to prevent second breast cancer. Ann Oncol 17:1065\u20131071","journal-title":"Ann Oncol"},{"key":"1370_CR3","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2001.19.6.1664","volume":"19","author":"T Camerini","year":"2001","unstructured":"Camerini T, Mariani L, De Palo G, Marubini E, Di Mauro MG, Decensi A, Costa A, Veronesi U (2001) Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 19:1664\u20131670","journal-title":"J Clin Oncol"},{"key":"1370_CR4","first-page":"2032","volume":"9","author":"A Garaventa","year":"2003","unstructured":"Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De Bernardi B, Bellani FF, Formelli F (2003) Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9:2032\u20132039","journal-title":"Clin Cancer Res"},{"key":"1370_CR5","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1200\/JCO.2005.03.9271","volume":"24","author":"JG Villablanca","year":"2006","unstructured":"Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP (2006) Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children\u2019s Oncology Group (CCG 09709). J Clin Oncol 24:3423\u20133430","journal-title":"J Clin Oncol"},{"key":"1370_CR6","first-page":"843","volume":"15","author":"F Formelli","year":"1987","unstructured":"Formelli F, Carsana R, Costa A (1987) N(4-hydroxyphenyl)retinamide (4-HPR) lowers plasma retinol levels in rats. Med Sci Res 15:843\u2013844","journal-title":"Med Sci Res"},{"key":"1370_CR7","first-page":"6149","volume":"49","author":"F Formelli","year":"1989","unstructured":"Formelli F, Carsana R, Costa A, Buranelli F, Campa T, Dossena G, Magni A, Pizzichetta M (1989) Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 49:6149\u20136152","journal-title":"Cancer Res"},{"key":"1370_CR8","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.1993.11.10.2036","volume":"11","author":"F Formelli","year":"1993","unstructured":"Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, Moglia D, De Palo G, Costa A, Veronesi U (1993) Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11:2036\u20132042","journal-title":"J Clin Oncol"},{"key":"1370_CR9","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1167\/iovs.05-0820","volume":"46","author":"RA Radu","year":"2005","unstructured":"Radu RA, Han Y, Bui TV, Nusinowitz S, Bok D, Lichter J, Widder K, Travis GH, Mata NL (2005) Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 46:4393\u20134401 Erratum in: Invest Ophthalmol Vis Sci (2006) 47:3735","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1370_CR10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature03711","volume":"436","author":"Q Yang","year":"2005","unstructured":"Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356\u2013362","journal-title":"Nature"},{"key":"1370_CR11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00280-007-0649-7","volume":"62","author":"F Formelli","year":"2008","unstructured":"Formelli F, Cavadini E, Luksch R, Garaventa A, Villani MG, Appierto V, Persiani S (2008) Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother Pharmacol 62:655\u2013665","journal-title":"Cancer Chemother Pharmacol"},{"key":"1370_CR12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/86.2.105","volume":"86","author":"A Decensi","year":"1994","unstructured":"Decensi A, Torrisi R, Polizzi A, Gesi R, Bresso V, Rolando M, Rondanina G, Orengo MA, Formelli F, Costa A (1994) Effest of the synthetic retinoid fenretinide on dark adaptation and ocular surface. J Natl Cancer Inst 86:105\u2013110","journal-title":"J Natl Cancer Inst"},{"key":"1370_CR13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1200\/JCO.2005.02.9934","volume":"24","author":"A Guerrieri-Gonzaga","year":"2006","unstructured":"Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Formelli F, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, Decensi A (2006) Preliminary results on safety and activity of a randomized, double-blind, 2\u00a0\u00d7\u00a02 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 24:129\u2013135","journal-title":"J Clin Oncol"},{"key":"1370_CR14","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/jn\/122.10.1999","volume":"122","author":"JE Smith","year":"1992","unstructured":"Smith JE, Lawless DC, Green MH, Moon RC (1992) Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenil)retinamide (Fenretinide). J Nutr 122:1999\u20132009","journal-title":"J Nutr"},{"key":"1370_CR15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0014-5793(92)81046-O","volume":"308","author":"R Berni","year":"1992","unstructured":"Berni R, Formelli F (1992) In vitro interaction with plasma retinol-binding protein and its functional consequences. FEBS 308:43\u201345","journal-title":"FEBS"},{"key":"1370_CR16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1096\/fasebj.7.12.8375617","volume":"7","author":"R Berni","year":"1993","unstructured":"Berni R, Clerici M, Malpeli G, Cleris L, Formelli F (1993) Retinoids: in vitro interaction with retinol-binding protein and influence on plasma retinol. FASEB J 7:1179\u20131184","journal-title":"FASEB J"},{"key":"1370_CR17","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/1055-9965.EPI-06-0183","volume":"15","author":"N Colombo","year":"2006","unstructured":"Colombo N, Formelli F, Cant\u00f9 MG, Parma G, Gasco M, Argusti A, Santinelli A, Montironi R, Cavadini E, Baglietto L, Guerrieri-Gonzaga A, Viale G, Decensi A (2006) A phase I\u2013II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. Cancer Epidemiol Biomarkers Prev 15:1914\u20131919","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1370_CR18","doi-asserted-by":"crossref","unstructured":"Schneider BJ, Worden FP, Gadgeel SM, Parchment RE, Hodges CM, Zwiebel J, Dunn RL, Wozniak AJ, Kraut M, Kalemkerian GP (2009) Phase II trial of fenretinide (SNC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs 27:571\u2013578","DOI":"10.1007\/s10637-009-9228-6"},{"key":"1370_CR19","first-page":"34","volume":"12","author":"F Formelli","year":"2003","unstructured":"Formelli F, Camerini T, Cavadini E, Appierto V, Villani MG, Costa A, De Palo G, Di Mauro MG, Veronesi U (2003) Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome. Cancer Epidemiol Biomarkers Prev 12:34\u201341","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1370-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1370-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1370-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:07:08Z","timestamp":1559038028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1370-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,8]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["1370"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1370-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,8]]}}}